Although several prior pharmacologic reports have assessed the therapeutic efficacy of CHEK1 inhibitors in MM, the detailed molecular mechanism of CHECK1-mediated promotion of MM has not yet been elucidated [17–21]. This evidence concerns the gene CHEK1 and Miyoshi myopathy.